作者: Tarik Tihan , Poonam Vohra , Mitchel S. Berger , G. Evren Keles
DOI: 10.1007/S11060-005-4897-2
关键词: Who grade 、 Perspective (graphical) 、 Gemistocytic Astrocytoma 、 Intensive care medicine 、 Astrocytoma 、 Gemistocytic Astrocytomas 、 Pathology 、 Pathological 、 Clinical significance 、 Diffuse Astrocytoma 、 Medicine
摘要: Gemistocytic astrocytoma still continues to be enigmatic; both in terms of definition and prognostic implications. The major issue contention has been the clinical relevance this pathological entity. currently accepted gemistocytic requires 20% or more gemistocytes, considers neoplasm as a diffuse astrocytoma, which is WHO grade II tumor. Some suggest that morphology should considered evidence higher astrocytoma. However, there no consensus on percentage gemistocytes associated with worse prognosis than otherwise expected. Given reported cases series, it not clear portends aggressive biology when all else equal. There need for studies sufficient numbers well-matched non-gemistocytic astrocytic neoplasms decide whether upgrading tumor 'significant' number justifiable. This article presents critical review existing brief mention our experience from perspective.